FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617463860> ?p ?o ?g. }

• W2617463860 endingPage "912" @default.
• W2617463860 startingPage "905" @default.
• W2617463860 abstract "Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA.This was a multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20-80 years, and an Eastern Cooperative Oncology Group performance status (PS) of 0-2. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), overall survival (OS), overall PFS, and safety.Between April 2010 and November 2012, 24 patients were enrolled from 12 institutions. The median age of the patients was 63 years (range 31-79) and there was a male/female ratio of 18/6. The number of PS 0/1 patients was 17/7 and locally advanced/metastatic disease was seen in 2/22 patients, respectively. The primary tumor site was the duodenum in 14 patients (58%) and jejunum in 10 patients (42%). The median follow-up time was 14.7 months (3.7-40.3). The 1-year PFS was 23.3%. The ORR was 9/20 (45%). The median PFS and OS times were 5.9 months (95% confidence interval [CI] 3.0-10.2) and 17.3 months (95% CI 11.7-19.0), respectively. Major grade 3/4 toxicities were neutropenia (38%), anemia/peripheral neuropathy (25%), and stenosis (17%). There were no treatment-related deaths.Although the primary endpoint was not met, mFOLFOX6 showed effective and good tolerance as a first-line treatment for SBA." @default.
• W2617463860 created "2017-06-05" @default.
• W2617463860 creator A5015023308 @default.
• W2617463860 creator A5019358201 @default.
• W2617463860 creator A5022854492 @default.
• W2617463860 creator A5027389118 @default.
• W2617463860 creator A5030125501 @default.
• W2617463860 creator A5032914911 @default.
• W2617463860 creator A5033552897 @default.
• W2617463860 creator A5037711521 @default.
• W2617463860 creator A5038876397 @default.
• W2617463860 creator A5044214575 @default.
• W2617463860 creator A5048191593 @default.
• W2617463860 creator A5058445735 @default.
• W2617463860 creator A5072512404 @default.
• W2617463860 creator A5090659723 @default.
• W2617463860 date "2017-05-23" @default.
• W2617463860 modified "2023-10-16" @default.
• W2617463860 title "A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma" @default.
• W2617463860 cites W130380703 @default.
• W2617463860 cites W1562837156 @default.
• W2617463860 cites W1594306308 @default.
• W2617463860 cites W1979161693 @default.
• W2617463860 cites W1979538859 @default.
• W2617463860 cites W1993602329 @default.
• W2617463860 cites W2006841529 @default.
• W2617463860 cites W2014207760 @default.
• W2617463860 cites W2016886132 @default.
• W2617463860 cites W2021499017 @default.
• W2617463860 cites W2023603116 @default.
• W2617463860 cites W2028671833 @default.
• W2617463860 cites W2033837839 @default.
• W2617463860 cites W2040935952 @default.
• W2617463860 cites W2049716523 @default.
• W2617463860 cites W2055953960 @default.
• W2617463860 cites W2061272573 @default.
• W2617463860 cites W2068836281 @default.
• W2617463860 cites W2069104763 @default.
• W2617463860 cites W2069672176 @default.
• W2617463860 cites W2070217055 @default.
• W2617463860 cites W2075657881 @default.
• W2617463860 cites W2080436435 @default.
• W2617463860 cites W2081457097 @default.
• W2617463860 cites W2085705101 @default.
• W2617463860 cites W2087538079 @default.
• W2617463860 cites W2089841647 @default.
• W2617463860 cites W2111365003 @default.
• W2617463860 cites W2122959891 @default.
• W2617463860 cites W2123867534 @default.
• W2617463860 cites W2129754451 @default.
• W2617463860 cites W2135103642 @default.
• W2617463860 cites W2157552285 @default.
• W2617463860 cites W2158734599 @default.
• W2617463860 cites W2161686366 @default.
• W2617463860 cites W2287506861 @default.
• W2617463860 cites W2339726334 @default.
• W2617463860 cites W4254975047 @default.
• W2617463860 doi "https://doi.org/10.1007/s10147-017-1138-6" @default.
• W2617463860 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5608770" @default.
• W2617463860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28536826" @default.
• W2617463860 hasPublicationYear "2017" @default.
• W2617463860 type Work @default.
• W2617463860 sameAs 2617463860 @default.
• W2617463860 citedByCount "28" @default.
• W2617463860 countsByYear W26174638602018 @default.
• W2617463860 countsByYear W26174638602019 @default.
• W2617463860 countsByYear W26174638602020 @default.
• W2617463860 countsByYear W26174638602021 @default.
• W2617463860 countsByYear W26174638602022 @default.
• W2617463860 countsByYear W26174638602023 @default.
• W2617463860 crossrefType "journal-article" @default.
• W2617463860 hasAuthorship W2617463860A5015023308 @default.
• W2617463860 hasAuthorship W2617463860A5019358201 @default.
• W2617463860 hasAuthorship W2617463860A5022854492 @default.
• W2617463860 hasAuthorship W2617463860A5027389118 @default.
• W2617463860 hasAuthorship W2617463860A5030125501 @default.
• W2617463860 hasAuthorship W2617463860A5032914911 @default.
• W2617463860 hasAuthorship W2617463860A5033552897 @default.
• W2617463860 hasAuthorship W2617463860A5037711521 @default.
• W2617463860 hasAuthorship W2617463860A5038876397 @default.
• W2617463860 hasAuthorship W2617463860A5044214575 @default.
• W2617463860 hasAuthorship W2617463860A5048191593 @default.
• W2617463860 hasAuthorship W2617463860A5058445735 @default.
• W2617463860 hasAuthorship W2617463860A5072512404 @default.
• W2617463860 hasAuthorship W2617463860A5090659723 @default.
• W2617463860 hasBestOaLocation W26174638601 @default.
• W2617463860 hasConcept C121608353 @default.
• W2617463860 hasConcept C126322002 @default.
• W2617463860 hasConcept C141071460 @default.
• W2617463860 hasConcept C203092338 @default.
• W2617463860 hasConcept C2776694085 @default.
• W2617463860 hasConcept C2776705615 @default.
• W2617463860 hasConcept C2777063308 @default.
• W2617463860 hasConcept C2778248108 @default.
• W2617463860 hasConcept C2778336483 @default.
• W2617463860 hasConcept C2780456651 @default.
• W2617463860 hasConcept C2780962732 @default.
• W2617463860 hasConcept C2781413609 @default.

• next